Compounds > l 372662
Page last updated: 2024-12-10

l 372662

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 372662: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5311202
CHEMBL ID306645
SCHEMBL ID17423352
MeSH IDM0291100

Synonyms (26)

Synonym
gtpl2253
l372662
L012255 ,
CHEMBL306645 ,
l-372662
1-(1-{2-methoxy-4-[1-(2-methyl-1-oxy-pyridin-3-ylmethyl)-piperidin-4-yloxy]-benzoyl}-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
bdbm50064711
1-[1-[2-methoxy-4-[1-[(2-methyl-1-oxidopyridin-1-ium-3-yl)methyl]piperidin-4-yl]oxybenzoyl]piperidin-4-yl]-4h-3,1-benzoxazin-2-one
SCHEMBL17423352
Q27078395
162045-26-3
3-((4-(3-methoxy-4-(4-(2-oxo-2h-benzo[d][1,3]oxazin-1(4h)-yl)piperidine-1-carbonyl)phenoxy)piperidin-1-yl)methyl)-2-methylpyridine1-oxide
3-((4-(3-methoxy-4-(4-(2-oxo-2h-benzo[d][1,3]oxazin-1(4h)-yl)piperidine-1-carbonyl)phenoxy)piperidin-1-yl)methyl)-2-methylpyridine 1-oxide
cid 5311202
unii-ns95dw687n
1-(1-(2-methoxy-4-(1-((2-methyl-1-oxidopyridin-1-ium-3-yl)methyl)piperidin-4-yl)oxybenzoyl)piperidin-4-yl)-4h-3,1-benzoxazin-2-one
piperidine, 1-(2-methoxy-4-((1-((2-methyl-3-pyridinyl)methyl)-4-piperidinyl)oxy)benzoyl)-4-(2-oxo-2h-3,1-benzoxazin-1(4h)-yl)-, n-oxide
ns95dw687n ,
piperidine, 1-(2-methoxy-4-((1-((2-methyl-1-oxido-3-pyridinyl)methyl)-4-piperidinyl)oxy)benzoyl)-4-(2-oxo-2h-3,1-benzoxazin-1(4h)-yl)-
2h-3,1-benzoxazin-2-one, 1,4-dihydro-1-(1-(2-methoxy-4-((1-((2-methyl-1-oxido-3-pyridinyl)methyl)-4-piperidinyl)oxy)benzoyl)-4-piperidinyl)-
3-((4-(3-methoxy-4-(4-(2-oxo-2h-benzo(d)(1,3)oxazin-1(4h)-yl)piperidine-1-carbonyl)phenoxy)piperidin-1-yl)methyl)-2-methylpyridine 1-oxide
1,4-dihydro-1-(1-(2-methoxy-4-((1-((2-methyl-1-oxido-3-pyridinyl)methyl)-4-piperidinyl)oxy)benzoyl)-4-piperidinyl)-2h-3,1-benzoxazin-2-one
MS-30483
l 372662
HY-15011
CS-0003696

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"71 mg/kg in the rat), excellent oral bioavailability (90% in the rat, 96% in the dog), good aqueous solubility (>8."( Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.
Bell, IM; Erb, JM; Freidinger, RM; Gallicchio, SN; Guare, JP; Guidotti, MT; Halpin, RA; Hobbs, DW; Homnick, CF; Kuo, MS; Lis, EV; Mathre, DJ; Michelson, SR; Pawluczyk, JM; Pettibone, DJ; Reiss, DR; Vickers, S; Williams, PD; Woyden, CJ, 1998)		0.3
" vasopressin receptor selectivity (> 500-fold), potency as an antagonist of oxytocin-induced uterine contractions in late gestation pregnant rhesus monkeys (AD50 = 36 micrograms/kg), oral bioavailability (F = 90% in dogs), and aqueous solubility (10 mg/mL)."( Progress in the development of oxytocin antagonists for use in preterm labor.
Bock, MG; Evans, BE; Freidinger, RM; Pettibone, DJ; Williams, PD, 1998)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Vasopressin V2 receptorHomo sapiens (human)Ki28.00000.00040.43453.9811AID513686
Oxytocin receptorHomo sapiens (human)Ki0.00410.00010.07180.9780AID151796
Vasopressin V1a receptorRattus norvegicus (Norway rat)Ki0.00080.00080.03000.1100AID513685
Vasopressin V1a receptorHomo sapiens (human)Ki3.20000.00020.62357.0300AID513684
Oxytocin receptorRattus norvegicus (Norway rat)Ki0.01500.00090.04890.2300AID151928
Vasopressin V2 receptor Rattus norvegicus (Norway rat)Ki9.70000.00030.97919.7000AID513687
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (63)

Processvia Protein(s)Taxonomy
positive regulation of systemic arterial blood pressureVasopressin V2 receptorHomo sapiens (human)
renal water retentionVasopressin V2 receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
activation of adenylate cyclase activityVasopressin V2 receptorHomo sapiens (human)
hemostasisVasopressin V2 receptorHomo sapiens (human)
positive regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
negative regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
positive regulation of gene expressionVasopressin V2 receptorHomo sapiens (human)
telencephalon developmentVasopressin V2 receptorHomo sapiens (human)
response to cytokineVasopressin V2 receptorHomo sapiens (human)
positive regulation of intracellular signal transductionVasopressin V2 receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V2 receptorHomo sapiens (human)
suckling behaviorOxytocin receptorHomo sapiens (human)
response to amphetamineOxytocin receptorHomo sapiens (human)
muscle contractionOxytocin receptorHomo sapiens (human)
cell surface receptor signaling pathwayOxytocin receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationOxytocin receptorHomo sapiens (human)
heart developmentOxytocin receptorHomo sapiens (human)
lactationOxytocin receptorHomo sapiens (human)
memoryOxytocin receptorHomo sapiens (human)
response to xenobiotic stimulusOxytocin receptorHomo sapiens (human)
positive regulation of norepinephrine secretionOxytocin receptorHomo sapiens (human)
telencephalon developmentOxytocin receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicOxytocin receptorHomo sapiens (human)
response to estradiolOxytocin receptorHomo sapiens (human)
response to progesteroneOxytocin receptorHomo sapiens (human)
response to anoxiaOxytocin receptorHomo sapiens (human)
response to cytokineOxytocin receptorHomo sapiens (human)
social behaviorOxytocin receptorHomo sapiens (human)
response to cocaineOxytocin receptorHomo sapiens (human)
maternal behaviorOxytocin receptorHomo sapiens (human)
sperm ejaculationOxytocin receptorHomo sapiens (human)
eating behaviorOxytocin receptorHomo sapiens (human)
response to peptide hormoneOxytocin receptorHomo sapiens (human)
estrous cycleOxytocin receptorHomo sapiens (human)
positive regulation of blood pressureOxytocin receptorHomo sapiens (human)
digestive tract developmentOxytocin receptorHomo sapiens (human)
positive regulation of synapse assemblyOxytocin receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicOxytocin receptorHomo sapiens (human)
positive regulation of penile erectionOxytocin receptorHomo sapiens (human)
ERK1 and ERK2 cascadeOxytocin receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionOxytocin receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisOxytocin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayOxytocin receptorHomo sapiens (human)
female pregnancyOxytocin receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinOxytocin receptorHomo sapiens (human)
positive regulation of vasoconstrictionOxytocin receptorHomo sapiens (human)
maternal process involved in parturitionOxytocin receptorHomo sapiens (human)
cellular response to hormone stimulusOxytocin receptorHomo sapiens (human)
maternal aggressive behaviorVasopressin V1a receptorHomo sapiens (human)
positive regulation of systemic arterial blood pressureVasopressin V1a receptorHomo sapiens (human)
generation of precursor metabolites and energyVasopressin V1a receptorHomo sapiens (human)
activation of phospholipase C activityVasopressin V1a receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVasopressin V1a receptorHomo sapiens (human)
negative regulation of female receptivityVasopressin V1a receptorHomo sapiens (human)
grooming behaviorVasopressin V1a receptorHomo sapiens (human)
blood circulationVasopressin V1a receptorHomo sapiens (human)
positive regulation of cell population proliferationVasopressin V1a receptorHomo sapiens (human)
positive regulation of heart rateVasopressin V1a receptorHomo sapiens (human)
positive regulation of glutamate secretionVasopressin V1a receptorHomo sapiens (human)
myotube differentiationVasopressin V1a receptorHomo sapiens (human)
calcium-mediated signalingVasopressin V1a receptorHomo sapiens (human)
telencephalon developmentVasopressin V1a receptorHomo sapiens (human)
positive regulation of cell growthVasopressin V1a receptorHomo sapiens (human)
positive regulation of prostaglandin biosynthetic processVasopressin V1a receptorHomo sapiens (human)
positive regulation of cellular pH reductionVasopressin V1a receptorHomo sapiens (human)
social behaviorVasopressin V1a receptorHomo sapiens (human)
cellular response to water deprivationVasopressin V1a receptorHomo sapiens (human)
maternal behaviorVasopressin V1a receptorHomo sapiens (human)
sperm ejaculationVasopressin V1a receptorHomo sapiens (human)
response to corticosteroneVasopressin V1a receptorHomo sapiens (human)
negative regulation of transmission of nerve impulseVasopressin V1a receptorHomo sapiens (human)
transport across blood-brain barrierVasopressin V1a receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V1a receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V1a receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V1a receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V1a receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
vasopressin receptor activityVasopressin V2 receptorHomo sapiens (human)
protein bindingVasopressin V2 receptorHomo sapiens (human)
peptide bindingVasopressin V2 receptorHomo sapiens (human)
peptide hormone bindingOxytocin receptorHomo sapiens (human)
peptide bindingOxytocin receptorHomo sapiens (human)
vasopressin receptor activityOxytocin receptorHomo sapiens (human)
oxytocin receptor activityOxytocin receptorHomo sapiens (human)
vasopressin receptor activityVasopressin V1a receptorHomo sapiens (human)
protein kinase C bindingVasopressin V1a receptorHomo sapiens (human)
protein bindingVasopressin V1a receptorHomo sapiens (human)
peptide hormone bindingVasopressin V1a receptorHomo sapiens (human)
V1A vasopressin receptor bindingVasopressin V1a receptorHomo sapiens (human)
peptide bindingVasopressin V1a receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
endosomeVasopressin V2 receptorHomo sapiens (human)
endoplasmic reticulumVasopressin V2 receptorHomo sapiens (human)
Golgi apparatusVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
membraneVasopressin V2 receptorHomo sapiens (human)
endocytic vesicleVasopressin V2 receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneVasopressin V2 receptorHomo sapiens (human)
perinuclear region of cytoplasmVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
plasma membraneOxytocin receptorHomo sapiens (human)
microvillusOxytocin receptorHomo sapiens (human)
adherens junctionOxytocin receptorHomo sapiens (human)
apical plasma membraneOxytocin receptorHomo sapiens (human)
plasma membraneOxytocin receptorHomo sapiens (human)
endosomeVasopressin V1a receptorHomo sapiens (human)
plasma membraneVasopressin V1a receptorHomo sapiens (human)
endocytic vesicleVasopressin V1a receptorHomo sapiens (human)
plasma membraneVasopressin V1a receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID513684Displacement of [3H]vasopressin from vasopressin V1a receptor in human liver tissue2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID18621Bioavailability in rat1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.
AID513697Oral bioavailability in rhesus monkey2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513700Aqueous solubility of the compound at pH 52010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513686Displacement of [3H]vasopressin from vasopressin V2 receptor in human kidney tissue2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID23592Half-life (t1/2) in rat following iv administration1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.
AID151928Binding affinity for rat oxytocin receptor (OT-R)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.
AID14460Maximum concentration (Cmax) in rat when administered orally1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.
AID513692Selectivity ratio of Ki for human oxytocin receptor Ki for human vasopressin V1a receptor2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID169766Evaluated for blocking OT-induced uterine contractions in rat1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.
AID513687Displacement of [3H]vasopressin from vasopressin V2 receptor in rat kidney tissue2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513685Displacement of [3H]vasopressin from vasopressin V1a receptor in rat liver tissue2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID169764Evaluated for blocking OT-induced uterine contractions in rat1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.
AID513689Inhibition of oxytocin-induced uterine contraction in intraduodenally dosed rat2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513682Displacement of [3H]-oxytocin from oxytocin receptor in human uterus tissue2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513701Half life in rhesus monkey2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513693Selectivity ratio of Ki for human oxytocin receptor Ki for human vasopressin V2 receptor2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513683Displacement of [3H]-oxytocin from oxytocin receptor in rat uterus tissue2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513690Oral bioavailability in rat2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513688Inhibition of oxytocin-induced uterine contraction in iv dosed rat2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID513695Oral bioavailability in chimpanzee2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Oral oxytocin antagonists.
AID151796Binding affinity for cloned human oxytocin receptor (OT-R)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.
AID1346469Human OT receptor (Vasopressin and oxytocin receptors)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glycine
[no description available]		2.0210alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		2.0210alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
opc 21268
OPC 21268: structure given in first source; vasopressin V1 receptor antagonist		2.0510
oxytocin
Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.		2.4220heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
l 371257
L 371257: structure given in first source		2.7130
l 368899
[no description available]		2.0510
gsk221149a
GSK221149A: highly selective oxytocin receptor antagonist; structure in first source		2.0510dipeptide
piperidines
Piperidines: A family of hexahydropyridines.		2.0210
obe001
OBE001: an oxytocin receptor antagonist		2.0510
ConditionIndicatedRelationship StrengthStudiesTrials
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.730
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		02.0510
Labor, Premature
[description not available]		01.9910